These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19996263)

  • 1. Obsessive-compulsive disorder following cavernous sinus thrombosis.
    Garyfallos G; Papazisis G; Katsigiannopoulos K; Bozikas VP; Adamopoulou A
    J Neuropsychiatry Clin Neurosci; 2009; 21(4):473-4. PubMed ID: 19996263
    [No Abstract]   [Full Text] [Related]  

  • 2. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Agid O; Lerer B
    J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
    [No Abstract]   [Full Text] [Related]  

  • 4. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.
    Gilbert AR; Moore GJ; Keshavan MS; Paulson LA; Narula V; Mac Master FP; Stewart CM; Rosenberg DR
    Arch Gen Psychiatry; 2000 May; 57(5):449-56. PubMed ID: 10807485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.
    Kamijima K; Murasaki M; Asai M; Higuchi T; Nakajima T; Taga C; Matsunaga H
    Psychiatry Clin Neurosci; 2004 Aug; 58(4):427-33. PubMed ID: 15298657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering.
    Murray MG; Newman RM
    Am J Psychiatry; 1997 Jul; 154(7):1037. PubMed ID: 9210761
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.
    Hollander E; Allen A; Steiner M; Wheadon DE; Oakes R; Burnham DB;
    J Clin Psychiatry; 2003 Sep; 64(9):1113-21. PubMed ID: 14628989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.
    Ninan PT
    Psychopharmacol Bull; 2003; 37 Suppl 1():89-96. PubMed ID: 14566204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.
    Strous RD; Patel JK; Zimmet S; Green AI
    Am J Psychiatry; 1999 Jun; 156(6):973-4. PubMed ID: 10360153
    [No Abstract]   [Full Text] [Related]  

  • 11. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
    Zohar J; Judge R
    Br J Psychiatry; 1996 Oct; 169(4):468-74. PubMed ID: 8894198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
    Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
    J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.
    Denys D; van der Wee N; van Megen HJ; Westenberg HG
    J Clin Psychopharmacol; 2003 Dec; 23(6):568-75. PubMed ID: 14624187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroanatomical correlates of naturalistic long-term outcome of obsessive-compulsive disorder treated with selective serotonin reuptake inhibitors.
    Narayanaswamy JC; Kalmady SV; Cherian AV; Venkatasubramanian G; Reddy JY
    J Clin Psychopharmacol; 2014 Apr; 34(2):282-5. PubMed ID: 24525636
    [No Abstract]   [Full Text] [Related]  

  • 19. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed-onset obsessive-compulsive symptoms after brain infarctions treated with paroxetine.
    Muneoka K; Shirayama Y; Kon K; Kawabe M; Kimura S
    Clin Neuropharmacol; 2011; 34(6):260-1. PubMed ID: 22104637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.